BioScrip first quarter income increases 19.0 percent to $24 .8M BioScrip, Inc. today announced 2012 initial quarter financial outcomes. First quarter income was $155.6 million and net loss was $2.7 million, or $0.05 per share. Consolidated Altered EBITDA for the first one fourth was $8.4 million. Due to the sale of the business’s traditional and specialty pharmacy mail functions and community retail pharmacy shops on, may 4, 2012 , the business’s economic statements reflect the discontinued functions’ results for the 90 days ended March 31, 2012 and 2011 and resources transferred in the purchase by March 31, december 31 2012 and, 2011, individual from the continuing procedures of the continuing business.

BioTime announces outcomes of independent Hextend research in hemodynamically unstable trauma sufferers BioTime, Inc. The study, executed at the University of Miami Ryder Trauma Center, reported that preliminary resuscitation with Hextend was linked with no apparent coagulopathy and decreased mortality in comparison to fluid resuscitation without Hextend. Study design has many limitations, but that the full total results are warrant and encouraging a randomized controlled clinical trial. Proctor, Ph.D. At the University of Miami Ryder Trauma Center, a known level 1 trauma center, june 2008 through from December 2008. The total outcomes were offered at the prestigious Southern Surgical Association 2009 Annual Interacting with in December by Drs. Alan S.